Internal validation of the prognostic value for ATP6V1G2 was performed using 669 glioma samples from TCGA, with the time-dependent ROC curve showing high predictive efficacy of ATP6V1G2 (Fig. 9A). This evidence concerns the gene ATP6V1G2 and central nervous system cancer.